EPO (erytropoëtine)

Quickstart highlights

Dosing & reconstitution guide

Standard protocol (1 mL = 4000 IU/mL)

A 4000 IU vial dissolved in 1 mL bacteriostatic water gives a concentration of 4000 IU/mL. Calculate your own dilution →

Reconstitution steps

1. Let the vial reach room temperature and wash your hands.
2. Disinfect both rubber stoppers with an alcohol swab.
3. Draw up 1 mL of bacteriostatic water.
4. Inject the water slowly down the glass wall, not directly onto the powder.
5. Swirl gently until clear — never shake.
6. Label the vial with date and concentration and refrigerate.

Supplies needed

• EPO (erytropoëtine) vial (4000 IU)
• Bacteriostatic water
• Mixing syringe (1–3 mL) and U-100 insulin syringes
• Alcohol swabs and sharps container

Protocol overview

Dosing protocol in research

Values as described in literature and research protocols; not dosing advice.

Storage instructions

• Lyophilised (powder): cool, dry and dark; long-term at −20 °C.
• After reconstitution: refrigerator at 2–8 °C, use within ~4 weeks.
• Avoid repeated freezing and thawing.

Important notes

How this works

Erythropoietin (EPO) is a glycoprotein hormone primarily produced in the kidneys. It serves as the main regulator of erythropoiesis. Researchers study its synthetic variants to treat anemia and influence oxygen transport in the blood.

EPO binds to specific receptors on erythroid progenitor cells in the bone marrow. This binding activates the JAK2 signaling pathway, preventing programmed cell death (apoptose) of these cells. As a result, more cells mature into functional red blood cells. Synthetic epoetins work similarly to the endogenous hormone but often differ in their glycosylation patterns. The half-life of standard epoetin alfa is approximately 4 to 6 hours when administered intravenously. Long-acting variants, such as darbepoetin alfa, remain in circulation significantly longer.

Extensive clinical trials exist for EPO use in kidney failure and following chemotherapy. Studies also focus on neuroprotective effects in animal models, though human results remain inconclusive. The substance is on the WADA prohibited list due to its performance-enhancing potential in endurance sports. Researchers are currently investigating new variants that offer tissue protection without stimulating blood cell production. The safety of long-term use outside of medical guidelines has not been established.

Potential benefits & side effects

Effects described in research

• Increased haemoglobin and oxygen transport

Common side effects

• Increased blood viscosity
• High blood pressure
• Thrombosis
• Headache

An excessive concentration of red blood cells increases blood viscosity, which can lead to thrombosis or stroke. Users frequently report an increase in blood pressure. There is a lack of data regarding the long-term consequences of EPO use in healthy individuals.

Contraindications

• Pregnancy or breastfeeding
• Active or prior cancer
• Under 18 years of age
• Uncontrolled hypertension
• History of thrombosis

Lifestyle factors

• Keep a log of doses, timing and observed effects.
• Adequate sleep, hydration and a stable diet.

Injection technique

• Choose a site with subcutaneous fat: abdomen (5 cm from the navel), thigh or back of upper arm.
• Disinfect, pinch a skin fold and insert at a 45–90° angle.
• Inject slowly, wait 5 seconds and withdraw.
• Rotate sites and use each needle once.

Recommended source

Quality varies widely between suppliers. Look for an independent HPLC/MS lab report per batch, purity ≥ 98% and clear storage and shipping conditions.

As a reference we use the EPO (erytropoëtine) from PeptideWinkel, which publishes lab reports per batch.

Frequently asked questions